Protara Therapeutics' TARA-002 shows promising early data in bladder cancer, with a 72% complete response rate at 6 months in a small phase 2 trial. Financially, TARA has 7-8 quarters of funds ...

Protara Therapeutics has closed a $100 million public offering to fund clinical trials of a bladder cancer drug.

Protara Therapeutics (NASDAQ:TARA) was able to report positive phase 2 results using its drug TARA-002 to treat high-risk non-muscle invasive bladder cancer [NMIBC] patients. This mid-stage study ...

Protara believes that TARA-002 has significant potential to become an important treatment option for NMIBC patients. Bladder cancer ranks as the sixth most common cancer in the United States ...

Flatiron-based drug discovery company Protara Therapeutics raised roughly ... of the company's signature drug for the treatment of bladder cancer. The deal is the single biggest capital raise ...

NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics ... 2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC). The data will be featured NEW YORK, Nov ...

Bladder cancer is a cancer that forms in tissues of the bladder. Most bladder cancers are transitional cell carcinomas (cancer that begins in cells that normally make up the inner lining of the ...

Treatment with UGN-102 has shown promise as a non-surgical alternative when compared with a surgical approach for certain ...

Protara's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic ...

"These findings address a significant unmet need for bladder cancer patients and could improve their quality of life," said lead researcher Dr. Mark Tyson, a urologic oncologist at the Mayo Clinic ...